Kiora Pharmaceuticals (KPRX) Corporate presentation summary

Pipeline overview

• KIO-401 is a Phase 3-ready oral calpain inhibitor for CRAO, with planned development in NAION and global rights outside Asia.

• KIO-301 is a molecular photoswitch in Phase 2 for advanced retinitis pigmentosa; the trial is actively enrolling.

• KIO-301 partners Théa, Senju Pharmaceutical and Chong Kun Dang Pharmaceutical; potential milestones exceed $118M for development and regulatory and $431M for commercial milestones, plus royalties into the low 20% range.

KIO-401 in CRAO

• Senju’s Japanese Phase 3 trial showed an overall trend on the primary endpoint, with p=0.0949; in patients legally blind at baseline, 12-week improvement was ~21 ETDRS letters vs ~9 for placebo, p=0.0195.

• In the Japanese Phase 3 safety results, any TEAE occurred in 30.3% with KIO-401 vs 39.4% with placebo; no serious study drug-related TEAEs were reported in either arm.

• Planned global Phase 3: randomized, double-masked trial of ~144 patients, treated within 48 hours of symptom onset; primary endpoint is best-corrected visual acuity.

KIO-401 in NAION

• NAION has no approved therapy; most patients present days to weeks after onset, and roughly 10% continue worsening over the following four weeks.

• Planned Phase 2b is a randomized, double-masked trial of ~272 patients, with treatment within 14 days; primary endpoint is best-corrected visual acuity.